Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence (NCT06721351)
Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence -DRES-POCAI: AI - Clinical Intervention at San Ysidro Health
🩺 Plain-English Summary (8th-Grade Level)
This research study is being conducted to improve eye care by using artificial intelligence (AI) to make diabetic eye screenings faster and more accessible. AI technology mimics human decision-making, enabling computers and systems to analyze medication information. Specifically for this screening, AI examines digital images of the eye and based on that information, may identify if a participant has diabetic retinopathy. It can assist doctors in making decisions about a participant's diagnosis, treatment or care plans to improve patient care. This is a collaboration between San Ysidro Health (SYHealth), University of California, San Diego (UC San Diego), and Eyenuk. The Kaiser Permanente Augmented Intelligence in Medicine and Healthcare Initiative (AIM-HI) awarded SYHealth funds to demonstrate the value of AI technologies in diverse, real-world settings.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (6 items).
Location: San Ysidro Health Chula Vista — Chula Vista, California
Age range: 22 Years
🧪 Interventions in This Study
- Diabetic Retinopathy screening Point of Care Artificial Intelligence (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- have a prior diagnosis of DR, macular edema, or retinal vascular occlusion;
- have persistent visual Impairment in one or both eyes;
- history of ocular injections, laser treatment of the retina, or intraocular surgery (excluding cataract surgery);
- pregnant women; and
- diagnosis of mental or degenerative disease that prevents self-consent for the study.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (3 Sites)
- San Ysidro Health Chula Vista — Chula Vista, California
- San Ysidro Health - Comprehensive Health Center - Ocean View — San Diego, California
- San Ysidro Health King-Chavez Health Center — San Diego, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: Participants will receive a copy of the results immediately after completion of the screening.
More studies in Diabetic Retinopathy (DR)
- Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE) — Chicago, Illinois
- Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) — Phoenix, Arizona
- Assessment of AI Program 'DRISTi' as a Screening Tool — Oxford, North Carolina
Explore by condition: All Diabetic Retinopathy (DR) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.